These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32070422)

  • 1. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis.
    Ledoult E; Launay D; Béhal H; Mouthon L; Pugnet G; Lega JC; Agard C; Allanore Y; Jego P; Fauchais AL; Harlé JR; Berthier S; Aouba A; Mekinian A; Diot E; Truchetet ME; Boulon C; Duhamel A; Hachulla E; Sobanski V;
    Arthritis Res Ther; 2020 Feb; 22(1):30. PubMed ID: 32070422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision.
    Correia C; Mawe S; Lofgren S; Marangoni RG; Lee J; Saber R; Aren K; Cheng M; Teaw S; Hoffmann A; Goldberg I; Cowper SE; Khatri P; Hinchcliff M; Mahoney JM
    Arthritis Res Ther; 2020 Mar; 22(1):48. PubMed ID: 32171325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study.
    Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Miura S; Toyama T; Yoshizaki A; Sumida H; Asano Y; Oba K; Sato S
    Arthritis Res Ther; 2019 May; 21(1):129. PubMed ID: 31138286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between nailfold microvascular damage and skin involvement in systemic sclerosis patients.
    Ruaro B; Pizzorni C; Paolino S; Smith V; Ghio M; Casabella A; Alessandri E; Patané M; Sulli A; Cutolo M
    Microvasc Res; 2019 Sep; 125():103874. PubMed ID: 30974112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.
    Bagnato GL; Roberts WN; Fiorenza A; Arcuri C; Certo R; Trimarchi F; Ruggeri RM; Bagnato GF
    Endocrine; 2016 Feb; 51(2):291-7. PubMed ID: 25994300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of menopause on the modified Rodnan skin score in systemic sclerosis.
    Vinet É; Bernatsky S; Hudson M; Pineau CA; Baron M;
    Arthritis Res Ther; 2014 Jun; 16(3):R130. PubMed ID: 24957704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
    Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
    Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.
    Li H; Furst DE; Jin H; Sun C; Wang X; Yang L; He J; Wang Y; Liu A
    Arthritis Res Ther; 2018 Aug; 20(1):181. PubMed ID: 30115105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
    Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
    Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in skin thickening in systemic sclerosis associated with improved survival.
    Steen VD; Medsger TA
    Arthritis Rheum; 2001 Dec; 44(12):2828-35. PubMed ID: 11762943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
    Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
    Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
    Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
    Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.